Full-Time

Design Engineer 2

Cooper Companies

Cooper Companies

201-500 employees

Global medical devices and vision care

No salary listed

Cornwall, UK

In Person

Bachelor's, Master's

Category
Biology & Biotech (1)

Get referred to Cooper Companies

See people who can refer or advise you

Requirements
  • MEng or BEng (Hons) Degree or equivalent
  • Highly Proficient in engineering designs and creation of engineering drawings – required
  • Medical device development experience with thorough understanding of design control guidelines including verification and validation methods – required
  • Proficiency with engineering first principles and analytical methods including simulation modeling
  • Understanding of Design for Manufacturing and Assembly (DFMA) – required
  • Understanding of statistical methods including design of experiments – required
  • Hands-on craft skills and experience with building, fixing, servicing and/or fabricating concepts, fixtures, prototypes or similar – required
  • Experience with FEA and/or simulation mathematical modeling – preferred
  • Experience with translating customer to product requirements, conducting harm-based risk analysis and defining acceptance criteria – preferred
  • Experience with electro-mechanical, robotic, or digital systems – preferred
  • Experience with Design for Six Sigma (DFSS) – preferred
  • Experience in drafting testing protocols and reports. - required
  • Experience with identifying latent user needs and front-end of innovation process – preferred
Responsibilities
  • Design and develop components and assemblies using first principles, Lead development of product or sub-systems for complex electromechanical products and analyze / simulate design to understand key parameters and sensitivities. Establish design feasibility by testing circuit and demonstrating statistical capability for critical functions.
  • Define design inputs (i.e., product requirements), develop design outputs (i.e., product specifications), define technical strategies for an adequate verification and validation approach. Drive successful verification and validation testing.
  • Ideate, conceptualize, and build concepts and prototypes to aid incubation of new opportunities or down-select wining solutions for new product developments, upgrades, or improvements.
  • Create simulation and mathematical models as appropriate to demonstrate functional feasibility of technical solution based on experimental, numerical, statistical, and/or finite-elements tools and techniques.
  • Participate in troubleshooting, root-cause analysis and devise solutions and approaches for solving technical problems (solution gameplan) and overcoming development challenges in an inclusive and collaborative fashion.
  • Develop test methods and fixtures for products, components, and systems simulation, evaluation, and verification testing including creating formal Verification test protocols, run tests, and write Verification test reports.
  • May communicate key technical content to parties within and outside of own function (R&D). May have responsibility for communicating with parties external to the organization and manage external development partners to meet project deliverables on time.
  • Deliver agreed project outcomes on-time and on-budget per project plan.
  • Manage your assignedproject tasks, workstreams, and deliverables ensuring full alignment with the overall project plan and business objectives.
  • Report to Project lead on your assigned tasks, ensuring early escalation and identification of project risks.
  • Participate in design review and DFMA activities.
  • Aid in the effective cross-functional collaboration ensuring timely and efficient delivery of target business outcomes.
  • Contribute to the assessment of new opportunities, acquisition targets, competitive products, and Intellectual Properties (IP’s) to aid competitiveness and differentiation of our business offerings.
  • Support scoping, project planning and product requirement definition for new product development, upgrades, or line extensions as appropriate.
  • Contribute to the selection, evaluation, and implementation of new tools, techniques, and best practices to ensure state-of-the-art product development capabilities and best practices.
  • Effectively and timely communicate (written and verbal) progress status updates associated with project issues.
  • Ensure adherence to medical devices design control compliance by ensuring all applicable safety, quality and regulatory guidelines and policies are followed to develop safe and effective products.
  • Maintain technical documentation for project and products as applicable per company quality standards, policies, and procedures and well as engineering best practices and functional excellence requirements.
Desired Qualifications
  • Experience with FEA and/or simulation mathematical modeling – preferred
  • Experience with translating customer to product requirements, conducting harm-based risk analysis and defining acceptance criteria – preferred
  • Experience with electro-mechanical, robotic, or digital systems – preferred
  • Experience with Design for Six Sigma (DFSS) – preferred
  • Experience with identifying latent user needs and front-end of innovation process – preferred

Cooper Companies operates in two main areas: CooperVision and CooperSurgical. CooperVision makes a wide range of contact lenses to correct vision, supported by product development, manufacturing, and global distribution. CooperSurgical offers medical devices, fertility, and genomic products for women’s health, covering care from contraception through advanced reproductive treatments, with a vertically integrated model that controls research, development, manufacturing, and distribution. Compared with competitors, the company combines vision care and women’s health in one group and maintains end-to-end control of its product lifecycle, enabling integrated supply and service delivery to healthcare providers and patients worldwide. Its goal is to improve health outcomes for people through accessible contact lenses and comprehensive women’s health products and services, across the globe.

Company Size

201-500

Company Stage

IPO

Headquarters

Pleasanton, California

Founded

1958

Get referred to Cooper Companies

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • September 9, 2026 guidance raised fiscal 2026 revenue to $4.229-$4.252 billion.
  • MyDay MiSight and clariti launches are expanding across Japan, EMEA, and APAC.
  • Free cash flow reached $273 million in Q3 fiscal 2026, supporting $1 billion buybacks.

What critics are saying

  • CooperSurgical's 2023 embryo-media recall triggered $271.6 million charges and 140-plus lawsuits.
  • CooperVision's U.S. channel inventory reductions flattened Q3 revenue and cut fiscal guidance.
  • Persistent IVF safety concerns can permanently damage CooperSurgical's franchise with fertility clinics.

What makes Cooper Companies unique

  • CooperVision's MyDay daily silicone hydrogel portfolio drives premium contact-lens share globally.
  • CooperSurgical spans fertility, genomics, and women’s health, covering the reproductive-care workflow.
  • Cooper sells in 130-plus countries, pairing global distribution with vertically integrated manufacturing.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Paid Vacation

Performance Bonus

Health Insurance

401(k) Retirement Plan

Life Insurance

Wellness Program

Professional Development Budget

Company News

Yahoo Finance
Sep 9th, 2026
CooperCompanies reports $1.08B Q1 revenue, up 7.9% year-on-year, beating estimates by 2.7%

CooperCompanies reported first-quarter revenues of $1.08 billion, up 7.9% year-on-year and exceeding analyst expectations by 2.7%. The medical device manufacturer, which focuses on vision care contact lenses and women's health products, also beat earnings per share estimates. The result came as the medical devices and supplies sector reported a strong quarter overall. Five tracked companies in the diversified category beat consensus revenue estimates by 2.9% on average, though next quarter's guidance came in 2.2% below expectations. Despite delivering the weakest full-year guidance update in the group, CooperCompanies' shares have risen 9% since reporting. The stock currently trades at $67.62.

Yahoo Finance
Sep 9th, 2026
Cooper Companies reports $271.8M record quarterly free cash flow, retains CooperSurgical after strategic review

Cooper Companies reported third-quarter fiscal 2026 revenue of $1.066 billion, up about 1%, with non-GAAP earnings per share rising 4% to $1.15. The company generated record quarterly free cash flow of $273 million, bringing year-to-date free cash flow to $528 million, up 86% year over year. CooperVision revenue remained flat at $717 million due to planned US channel inventory reductions, though underlying consumer demand continued growing at mid-single digits. CooperSurgical posted 3% organic growth, with fertility revenue increasing 5% to $141 million. The board concluded its strategic review and decided to retain CooperSurgical, whilst authorising an additional $1 billion in share repurchases. For the fourth quarter, Cooper expects flat to 2% organic revenue growth and non-GAAP EPS of $1.05 to $1.09.

Yahoo Finance
Sep 9th, 2026
CooperCompanies misses Q2 revenue estimates by 2.9%, cuts full-year guidance, stock drops 16.8%

CooperCompanies reported second-quarter revenue of $1.07 billion, missing analyst estimates of $1.10 billion. The medical device company's sales were flat year-on-year, whilst its operating margin improved to 20.8% from 16.6% in the same quarter last year. The company lowered its full-year revenue guidance to $4.24 billion at the midpoint, down from $4.30 billion, representing a 1.5% decrease. Adjusted earnings per share guidance was also reduced to $4.53 at the midpoint, a 1.9% decrease. Despite beating analyst expectations with adjusted EPS of $1.15 versus estimates of $1.12, the company's shares fell 16.8% following the announcement. CEO Al White cited reduced US channel inventory at CooperVision as weighing on results. CooperCompanies develops medical devices for vision care and women's health.

Associated Press
Sep 9th, 2026
CooperCompanies Q3 revenue up 1% to $1.07B, nets $307M UK tax benefit

CooperCompanies reported third quarter fiscal 2026 revenue of $1.066 billion, up 1% year-over-year. The medical device company posted GAAP diluted earnings per share of $2.24, compared with $0.49 in the prior year quarter, primarily driven by a $307.2 million discrete tax benefit from a favourable UK tax examination completion. Non-GAAP diluted EPS reached $1.15, up 4% from last year. Free cash flow increased 66% to $273.0 million. The company repurchased $339.1 million of common stock during the quarter. CooperVision revenue was flat at $717.0 million, whilst CooperSurgical revenue rose 2% to $349.2 million, with 6% fertility growth. The company cited reduced US channel inventory at CooperVision impacting results. CooperCompanies updated its fiscal 2026 guidance, projecting total revenue of $4.229-$4.252 billion and non-GAAP diluted EPS of $4.51-$4.55.

Yahoo Finance
Jun 8th, 2026
Cooper Companies' international revenue rises 7.9% to $1.08B, with EMEA contributing $287M

The Cooper Companies reported total revenue of $1.08 billion for the quarter ending April 2026, up 7.9% year over year. International markets contributed significantly to this performance, with EMEA generating $289.7 million (26.8% of total revenue) and Asia Pacific adding $130.6 million (12.1%). EMEA revenue exceeded Wall Street expectations by 5.18%, whilst Asia Pacific fell marginally short by 0.17%. The surgical and contact lens products maker's EMEA performance represented growth from $248.6 million in the year-ago quarter, though Asia Pacific revenue declined from $138.6 million over the same period. For the current fiscal quarter, analysts project total revenue of $1.12 billion, with EMEA expected to contribute $305.46 million and Asia Pacific $143.73 million.